2026 Q3 Portfolio Activity
In 2026 Q3, PERCEPTIVE ADVISORS LLC maintained a portfolio of 135 distinct positions. The most significant new addition was FREENOME INC, now representing 3.46% of the total fund value. They heavily accumulated shares in MODERNA INC, increasing the position by 40.0%. Conversely, PERCEPTIVE ADVISORS LLC completely exited their position in NUVALENT INC.
Position History
hover any row below to update
Loading…
Total Positions
135
Quarter
2026 Q3
Top Holding
PRAX (10.3%)
Top 10 Concentration
49.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 135
PERCEPTIVE ADVISORS LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 10.27% | 10.23% |
#1
Prev: #1
|
6.5 |
—
|
-11,205 | -0.6% |
P
S
|
2,024,781 | $589,676,971 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 5.36% | 2.25% |
#2
11
Prev: #13
|
6.1 |
—
|
2,238,853 | 26.9% |
P
S
|
10,573,735 | $307,695,689 | 2022 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 5.09% | 5.76% |
#3
1
Prev: #2
|
3.0 |
—
|
-1,038,553 | -24.0% |
P
S
|
3,280,943 | $292,102,355 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MRNA
PUT
MODERNA INC
|
PUT Option | 4.70% | 1.05% |
#4
22
Prev: #26
|
4.9 |
—
|
400,000 | 40.0% |
P
S
|
1,400,000 | $269,598,000 | 2020 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CELC
CELCUITY INC
|
Healthcare | 4.40% | 5.02% |
#5
2
Prev: #3
|
2.8 |
—
|
-17,406 | -0.5% |
P
S
|
3,179,794 | $252,857,219 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RYTM
RHYTHM PHARMACE...
|
Healthcare | 4.20% | 4.31% |
#6
1
Prev: #5
|
2.2 |
—
|
-53,739 | -2.1% |
P
S
|
2,532,556 | $241,137,320 | 2017 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 4.15% | 4.30% |
#7
1
Prev: #6
|
2.2 |
—
|
-1,574,500 | -19.5% |
P
S
|
6,510,961 | $238,105,844 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 4.00% | 3.96% |
#8
1
Prev: #7
|
2.1 |
—
|
-1,375,851 | -9.8% |
P
S
|
12,730,336 | $229,782,565 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 3.86% | 4.66% |
#9
5
Prev: #4
|
2.0 |
—
|
-192,200 | -16.5% |
P
S
|
971,521 | $221,341,629 | 2015 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TVTX
TRAVERE THERAPE...
|
Healthcare | 3.63% | 3.20% |
#10
2
Prev: #8
|
2.0 |
—
|
-209,661 | -5.6% |
P
S
|
3,542,913 | $208,606,717 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
FRNM
FREENOME INC
|
Healthcare | 3.46% | — |
#11
Prev: #—
|
4.9 |
—
|
12,606,053 | — |
NEW
|
12,606,053 | $198,545,334 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 2.93% | 2.67% |
#12
1
Prev: #11
|
1.7 |
—
|
-235,692 | -5.4% |
P
S
|
4,138,282 | $168,014,249 | 2023 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
INBX
INHIBRX BIOSCIE...
|
Healthcare | 2.25% | 1.85% |
#13
3
Prev: #16
|
1.4 |
—
|
-5,300 | -0.4% |
P
S
|
1,292,463 | $129,349,697 | 2021 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 2.22% | 1.57% |
#14
8
Prev: #22
|
3.4 |
—
|
1,051,207 | 24.3% |
P
S
|
5,371,629 | $127,361,324 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KARD
KARDIGAN INC
|
Healthcare | 2.11% | 2.94% |
#15
6
Prev: #9
|
1.8 |
—
|
no change | no change |
P
S
|
8,200,662 | $120,959,764 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MGTX
MEIRAGTX HLDGS ...
|
Healthcare | 2.07% | 2.19% |
#16
2
Prev: #14
|
1.8 |
—
|
no change | no change |
P
S
|
10,786,658 | $118,653,238 | 2018 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 2.05% | 1.81% |
#17
Prev: #17
|
1.3 |
—
|
-145,300 | -14.8% |
P
S
|
836,579 | $117,865,615 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IMTX
IMMATICS N.V
|
Healthcare | 1.72% | 1.58% |
#18
3
Prev: #21
|
2.7 |
—
|
863,060 | 8.3% |
P
S
|
11,246,516 | $98,744,410 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ZYME
ZYMEWORKS INC
|
Healthcare | 1.64% | 1.64% |
#19
Prev: #19
|
1.2 |
—
|
-637,452 | -15.2% |
P
S
|
3,545,501 | $93,920,321 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.56% | 1.92% |
#20
5
Prev: #15
|
0.6 |
—
|
-272,700 | -20.3% |
P
S
|
1,072,363 | $89,317,114 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 1.55% | 1.48% |
#21
3
Prev: #24
|
1.1 |
—
|
-94,500 | -17.9% |
P
S
|
433,100 | $88,898,106 | 2020 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SLDB
SOLID BIOSCIENC...
|
Healthcare | 1.50% | 1.79% |
#22
4
Prev: #18
|
1.6 |
—
|
no change | no change |
P
S
|
11,906,646 | $86,085,050 | 2022 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 1.49% | 1.55% |
#23
Prev: #23
|
1.1 |
—
|
-7,000 | -0.1% |
P
S
|
10,301,888 | $85,814,727 | 2002 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVLN
AVALYN PHARMACE...
|
Healthcare | 1.33% | 1.32% |
#24
1
Prev: #25
|
1.5 |
—
|
no change | no change |
P
S
|
2,675,296 | $76,219,183 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 1.17% | 1.58% |
#25
5
Prev: #20
|
0.5 |
—
|
-684,000 | -20.3% |
P
S
|
2,693,000 | $67,190,350 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
WAT
WATERS CORP
|
Healthcare | 1.03% | — |
#26
Prev: #—
|
3.9 |
—
|
135,000 | — |
NEW
|
135,000 | $59,317,650 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RGEN
REPLIGEN CORP
|
Healthcare | 0.91% | 0.51% |
#27
15
Prev: #42
|
2.4 |
—
|
24,244 | 9.8% |
P
S
|
272,456 | $52,374,217 | 2002 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AORT
ARTIVION INC
|
Healthcare | 0.84% | 0.59% |
#28
11
Prev: #39
|
2.8 |
—
|
375,000 | 21.6% |
P
S
|
2,112,290 | $48,202,458 | 2016 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 0.78% | 0.64% |
#29
5
Prev: #34
|
2.3 |
—
|
151,057 | 9.4% |
P
S
|
1,760,950 | $44,957,054 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRD
OPUS GENETICS I...
|
Healthcare | 0.76% | — |
#30
Prev: #—
|
3.8 |
—
|
9,000,000 | — |
NEW
|
9,000,000 | $43,560,000 | 2025 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SLS
CALL
SELLAS LIFE SCI...
|
CALL Option | 0.64% | — |
#31
Prev: #—
|
3.8 |
—
|
3,000,000 | — |
NEW
|
3,000,000 | $36,930,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GLPG
LAKEFRONT BIOTH...
|
Healthcare | 0.64% | — |
#32
Prev: #—
|
3.8 |
—
|
1,242,404 | — |
NEW
|
1,242,404 | $36,837,278 | 2015 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABT
ABBOTT LABORATO...
|
Healthcare | 0.59% | — |
#33
Prev: #—
|
3.7 |
—
|
345,225 | — |
NEW
|
345,225 | $34,118,587 | 2008 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BLSM
BLOSSOMHILL THE...
|
Healthcare | 0.59% | — |
#34
Prev: #—
|
3.7 |
—
|
1,812,193 | — |
NEW
|
1,812,193 | $33,779,278 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 0.55% | 0.71% |
#35
4
Prev: #31
|
0.2 |
—
|
-100,000 | -33.3% |
P
S
|
200,000 | $31,536,000 | 2015 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OBIO
ORCHESTRA BIOME...
|
Healthcare | 0.55% | 0.33% |
#36
22
Prev: #58
|
0.7 |
—
|
-300 | -0.0% |
P
S
|
5,037,606 | $31,333,909 | 2023 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SLS
PUT
SELLAS LIFE SCI...
|
PUT Option | 0.54% | 0.33% |
#37
19
Prev: #56
|
3.2 |
—
|
1,000,000 | 66.7% |
P
S
|
2,500,000 | $30,775,000 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 0.50% | 0.60% |
#38
2
Prev: #36
|
0.7 |
—
|
-157,000 | -5.9% |
P
S
|
2,510,441 | $28,920,280 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVR
ANTERIS TECHNOL...
|
Healthcare | 0.46% | 0.51% |
#39
4
Prev: #43
|
1.2 |
—
|
no change | no change |
P
S
|
3,425,476 | $26,615,949 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ANL
ADLAI NORTYE GR...
|
Healthcare | 0.46% | 0.31% |
#40
20
Prev: #60
|
0.7 |
—
|
-132,688 | -7.4% |
P
S
|
1,660,502 | $26,568,032 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
MINIMED GROUP I...
|
|
Unknown | 0.45% | — |
#41
Prev: #—
|
3.7 |
—
|
1,320,000 | — |
NEW
|
1,320,000 | $25,700,400 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
CTMX
CYTOMX THERAPEU...
|
Healthcare | 0.44% | 0.59% |
#42
4
Prev: #38
|
0.7 |
—
|
-1,171,124 | -11.2% |
P
S
|
9,268,061 | $25,209,126 | 2015 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 0.42% | 0.48% |
#43
1
Prev: #44
|
0.7 |
—
|
-49,000 | -6.3% |
P
S
|
724,342 | $24,337,891 | 2024 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SEPN
SEPTERNA INC
|
Healthcare | 0.39% | — |
#44
Prev: #—
|
3.7 |
—
|
567,479 | — |
NEW
|
567,479 | $22,205,453 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 0.37% | 0.56% |
#45
5
Prev: #40
|
0.6 |
—
|
-583,000 | -7.3% |
P
S
|
7,350,491 | $21,316,424 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 0.37% | — |
#46
Prev: #—
|
3.6 |
—
|
462,506 | — |
NEW
|
462,506 | $21,201,275 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 0.37% | 0.39% |
#47
5
Prev: #52
|
1.1 |
—
|
no change | no change |
P
S
|
6,627,501 | $21,009,178 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 0.36% | 0.90% |
#48
21
Prev: #27
|
0.1 |
—
|
-1,423,873 | -52.9% |
P
S
|
1,265,362 | $20,384,982 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
EOLS
EVOLUS INC
|
Healthcare | 0.34% | 0.26% |
#49
17
Prev: #66
|
1.1 |
—
|
no change | no change |
P
S
|
2,459,285 | $19,674,280 | 2019 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
YARW
YARROW BIOSCIEN...
|
Healthcare | 0.32% | — |
#50
Prev: #—
|
3.6 |
—
|
813,098 | — |
NEW
|
813,098 | $18,310,966 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-50 of 135 holdings